Dr. Elizabeth J. Ginn-Scott, MD

Dr. Ginn-Scott practices at Helen Herrmann Counseling Center in Red Bank, New Jersey.

Dr. Ginn-Scott's NPI, 1326252941, was assigned on May 10, 2007. Dr. Ginn-Scott holds New Jersey license 25MA08825000.

Dr. Ginn-Scott's primary practice is Helen Herrmann Counseling Center, at 270 Highway 35, Red Bank, NJ 07701. The practice phone is (732) 842-2000.

Dr. Ginn-Scott's primary practice is Helen Herrmann Counseling Center in Red Bank, New Jersey. The medical group on file is CPC Integrated Health. Dmand AI also links Dr. Ginn-Scott to 1 more medical group, named with a free account. Dr. Ginn-Scott's employer is on file too: a behavioral health center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ginn-Scott practices. Vendor and product names are available with a free account.

Psychiatry is Dr. Ginn-Scott's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Ginn-Scott is licensed in New Jersey.

CMS data shows 308 Medicare services from Dr. Ginn-Scott across 4 procedure codes in 2024, all of them office visits, for 49 Medicare patients. Medicare paid $22,819 for them. Every service was in an office.

CMS counts 49 Medicare patients who saw Dr. Ginn-Scott in 2024. The largest group is 65 to 74, with 21 patients. 75% of them have anxiety, and 75% have high cholesterol. 35% are also on Medicaid. Their average risk score is 1.25, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ginn-Scott's median patient age at 56, with 76% women.

In 2024, Dr. Ginn-Scott wrote 3,112 Medicare Part D claims for 100 patients. 96% of them were for generic drugs. CMS names the drug for 3,018 of them, across 46 drugs with 11 or more claims each, at $199,307 in total drug cost. In 2023, CMS named 3,029 claims across 48 drugs.

Dr. Ginn-Scott accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ginn-Scott as offering telehealth.

CMS Open Payments shows 85 general payments to Dr. Ginn-Scott from 19 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Otsuka America Pharmaceutical, Inc. paid the most, $168.